middle.news
Star Combo Pharma Focuses on Manufacturing as Revenue Falls 15% in FY26
4:59pm on Tuesday 25th of August, 2026 AEST
•
Pharmaceuticals
Read Story
Star Combo Pharma Focuses on Manufacturing as Revenue Falls 15% in FY26
4:59pm on Tuesday 25th of August, 2026 AEST
Key Points
15% decline in total group revenue to $23.57 million
Profit before tax down 90% to $528,472
10% revenue drop in core OEM manufacturing segment
Retail division closed in November 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Star Combo Pharma (ASX:S66)
OPEN ARTICLE